Stroke Trial, Recruiting NCT06733246 Sponsor: Ceretrieve Ltd. Condition: Stroke
Back to Stroke

Stroke Trial, Recruiting

NCT06733246
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who are 18 years of age or older
  • People showing signs of an acute ischemic stroke (a stroke caused by a blocked blood vessel in the brain)
  • People who can begin treatment within 24 hours of when their stroke symptoms started
  • People who were fully independent or had only very minor disability before the stroke (pre-stroke modified Rankin Score of 0 or 1)
  • People with a stroke severity score above 6 at the time of screening (measured using a standard stroke scale called the NIHSS)
  • If a clot-dissolving medication given through a drip (called IV thrombolysis) is appropriate, it must be started as soon as possible and no later than 4.5 hours after symptoms began, at the correct dose for the person's weight
  • People whose brain scan (angiography) confirms a blocked blood vessel in one of these locations: the internal carotid artery inside the skull, the M1 or M2 branches of the middle cerebral artery, the vertebral artery, or the basilar artery — and where the blockage can be reached by the clot-removal device used in this trial
  • People who have given valid, informed consent to participate, in line with local ethics committee requirements

Who may not be able to join:

  • People who are pregnant, breastfeeding, or have a positive pregnancy test at the time of admission
  • People whose stroke symptoms improve rapidly before enrolment, suggesting the stroke may be resolving on its own
  • People with a known serious allergic reaction to contrast dye used in medical imaging
  • People with a known sensitivity or allergy to nickel, titanium, or related metals (the device used in this trial contains these materials)
  • People already taking part in another research study that could affect the results of this trial
  • People with a known inherited or acquired bleeding disorder or blood clotting problem
  • People with a life expectancy of less than 90 days
  • People whose symptoms suggest a type of bleeding stroke called a subarachnoid haemorrhage, even if the initial scan appears normal
  • People where aortic dissection (a tear in the main artery from the heart) is suspected
  • People with another serious illness or condition that could affect the accuracy of neurological assessments, their survival, or their ability to complete follow-up visits
  • People who currently drink more than four alcoholic drinks per day on a regular or daily basis
  • People with a known artery condition (such as a narrowing or a previously placed stent) that would prevent the clot-removal device from safely reaching or being removed from the blocked vessel
  • People who would need a balloon procedure or stent placed in the carotid artery in the neck at the same time as the main procedure
  • People whose scan shows a tear in the carotid artery (carotid dissection)
  • People whose brain scan shows any of the following: bleeding in the brain, signs of a brain tumour (except a very small, slow-growing type called a meningioma), brain vessel inflammation (vasculitis), a large area of brain already damaged by the stroke (based on specific scoring thresholds or a core infarct volume above 70cc), a carotid artery tear or complete blockage in the neck requiring a stent, or any other finding that the treating doctor believes makes clot-removal treatment unsuitable
  • People with blockages in more than one brain artery region at the same time, or evidence of strokes in multiple areas of the brain

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 19 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Phone: +972-52-6511131

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Ceretrieve Ltd.
Registry
ClinicalTrials.gov
Start date
12 November 2024
Est. completion
30 May 2027

Where this trial is recruiting

🇩🇪 Germany

Primary endpoints

Number of Participants With Successful Reperfusion (mTICI 2b-3) Within Three Passes Without Rescue Therapy; Number of Participants With Symptomatic Intracranial Hemorrhage Within 24 (18-36) Hours Post-Procedure

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 19 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov